


# Financial Results and Business Update for the Quarter Ended December 31, 2025

**roivant**



**February 6, 2026**

# Forward-Looking Statements

This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, potential uses of cash and capital allocation, research and development plans, the anticipated timing, costs, design, conduct and results of our ongoing and planned preclinical studies and clinical trials for our product candidates, and any commercial potential of our product candidates following applicable regulatory approvals, are forward-looking statements.

These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this presentation and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements.

These forward-looking statements may be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the sections captioned “Risk Factors” and “Forward-Looking Statements” of our filings with the U.S. Securities and Exchange Commission, available at [www.sec.gov](http://www.sec.gov) and [investor.roivant.com](http://investor.roivant.com). We operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this presentation, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

## Non-GAAP Financial Information

The discussions during this conference call will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles (GAAP). Additional information regarding non-GAAP financial measures can be found on slide 29 and in our earnings release furnished with our Current Report on Form 8-K dated February 6, 2026. Any non-GAAP financial measures presented are not, and should not be viewed as, substitutes for financial measures required by U.S. GAAP, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies.

## Disclaimer

This presentation is intended for the investor community only; it is not intended to promote the product candidates referenced herein or otherwise influence healthcare prescribing decisions.

# Agenda

- **Roivant in 2026**
- **Brepocitinib: Positive Topline Results From BEACON Study in CS**
- **Additional Program Highlights**
- **Financial Update**
- **Q&A**

# Roivant in 2026

**roivant**

A decorative graphic in the bottom right corner consisting of a grid of thin red lines. The grid is composed of vertical and horizontal lines that curve and warp as they move towards the right, creating a sense of depth and movement. The lines are more densely packed on the left and become more sparse and curved on the right.

# Continued Execution Following a Strong 2025



**Positive Ph2  
results for  
brepocitinib in  
CS**



**Fully enrolled  
Ph2b study for  
IMVT-1402 in  
D2T RA**



**Fully enrolled  
Ph2 study for  
mosliciguat in  
PH-ILD**



**Immunovant  
\$550M common  
stock financing  
extends cash  
runway to GD  
commercial  
launch**

# 2026: Another Catalyst-Rich Year for Roivant



Brepocitinib NIU Ph3 topline data expected in 2H 2026



Initiation of brepocitinib CS Ph3 trial expected in 2026



Mosliciguat PH-ILD Ph2b topline data expected in 2H 2026



IMVT-1402 D2T RA potentially registrational topline data expected in 2H 2026




IMVT-1402 CLE PoC topline data expected in 2H 2026



LNP litigation jury trial in US Moderna case in March 2026

# High-Value Pipeline, Delivering Series of Near-Term Catalysts



# BEACON Top line Results

February 6, 2026



# Highlights of Phase 2 BEACON Study in Cutaneous Sarcoidosis (CS)

**Brepocitinib demonstrated highly compelling evidence of deep clinical benefit for patients with cutaneous sarcoidosis**

- Brepocitinib 45 mg achieved a placebo-adjusted improvement on mean CSAMI-A of 21.6 points ( $p < 0.0001$ )
- 100% of brepocitinib 45 mg patients compared to 14% of placebo patients achieved a CSAMI improvement of at least 10 points
- 62% of brepocitinib 45 mg patients compared to 0% of placebo patients achieved CSAMI-A  $< 5$  (functional remission)
- 69% of brepocitinib 45 mg patients compared to 0% of placebo patients achieved IGA gold standard Clear (0) / Almost Clear (1) with 2-point improvement

**Rapid onset of action with sustained benefit over time**

- Both brepocitinib doses achieved statistically significant separation from placebo on mean CSAMI-A at every study visit, starting with Week 4 (first visit)

**Both brepocitinib 45 mg and 15 mg substantially outperformed placebo across all endpoints measured**

- Dose dependent-response was seen on endpoints with highest clinical bar and patient reported outcomes

**Brepocitinib was well-tolerated throughout the 16-week treatment period, with No SAEs and all AEs graded mild or moderate in severity**

- Brepocitinib safety database includes over 1,500 patients and subjects, with a safety profile consistent with approved JAK1 and TYK2 inhibitors

**Cutaneous sarcoidosis represents a disease of high unmet need with no approved therapies**

- BEACON represents first ever positive placebo-controlled trial for any therapy, a breakthrough for the field

# CS: Urgency to Treat Due to Risk of Permanent Damage, Face and Scalp Involvement, and Psychosocial Impacts

Unlike many common inflammatory skin diseases, inadequately treated cutaneous sarcoidosis can rapidly cause permanent scarring and destruction of bone, cartilage, and hair follicles



Plaque cutaneous sarcoidosis affecting significant body surface area




Lupus pernio (papular and plaque cutaneous sarcoidosis)




Plaque cutaneous sarcoidosis resulting in scarring alopecia

# Cutaneous Sarcoidosis Alone Includes Eligible Population of ~40,000 Patients




1. Foundation for Sarcoidosis Research  
2. Haimovic, et al., J Am Acad Dermatol (2012)  
3. Altmeyer et al., Altmeyers Encycl (2025)

# JAK1/TYK2 Inhibition Distinctively Targets Key Pathogenic Process in Sarcoidosis: Polarization and Recruitment of Effector T Cells



# BEACON: Phase 2 Placebo-Controlled Study Evaluating Brepocitinib in Cutaneous Sarcoidosis



## Eligible Patients

Skin disease activity: CSAMI-A  $\geq$  10

## Permitted Background Therapy

Oral IST, antimalarial, tetracycline antibiotic, and/or OCS

## Primary Endpoint

Safety & Tolerability

## Efficacy Endpoints

CSAMI-A

CSA-IGA

Patient Reported Outcomes



# Baseline Demographics & Disease Activity

45 mg arm was most treatment-refractory group with longstanding disease, high damage, and high rates of plaque-predominant morphology

	Brepocitinib 45 mg (n = 13)	Brepocitinib 15 mg (n = 11)	Placebo (n = 7)
Mean Age (years) (± SD)	53.7 (8.14)	49.4 (11.57)	58.7 (6.18)
Sex (Female) – no. (%)	11 (85%)	3 (27%)	4 (57%)
Black race – no. (%)	11 (85%)	6 (55%)	6 (86%)
Duration of Skin Disease (years) (± SD)	10.2 (9.49)	4.1 (2.06)	10.3 (7.18)
Mean CSAMI-Activity Score (± SD)	34.9 (22.63)	32.4 (9.45)	32.9 (19.35)
Mean CSA-IGA Activity Score (± SD)	2.8 (0.44)	3.3 (0.65)	3.0 (0.82)
Plaque-predominant morphology* – no. (%)	11 (85%)	6 (55%)	3 (43%)
Mean CSAMI-Damage Score (± SD)	6.1 (6.09)	3.2 (2.23)	5.7 (5.28)
Background Therapy at Baseline – no. (%)			
Topical Corticosteroid	5 (39%)	4 (36%)	2 (29%)
Systemic Therapy (OCS, IST, or AM)	8 (62%)	5 (45%)	3 (43%)

\*Large, thick lesions associated with chronic course and a higher likelihood of recurrence (Wanat, 2015)

# Brepocitinib Achieved Rapid, Deep, Sustained Benefit on CSAMI-A CFB and IGA Clear/Almost Clear




$P < 0.05$ ; \*\*  $P < 0.0001$

CSAMI-A: Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity Score; MCID: minimal clinically important difference; IGA: investigator's global assessment


# 100% CSAMI-A Response Rate In Brepocitinib 45 mg Arm

All 45 mg participants achieved  $\geq 10$ -point CSAMI-A improvement (2x minimum clinically important difference) and 62% achieved functional remission

### Achievement of CSAMI-A $\geq 10$ -point Reduction at Week 16



### Achievement of CSAMI-A $< 5$ (Functional Remission) at Week 16



# Skindex-16 Shows Substantial Improvements in Health-related Quality of Life

## Skindex-16 assesses health-related QoL

16 items in 3 domains:

### Symptoms

Itching, Burning, Pain, Irritation


### Emotions

Persistence, Worry, Frustration, Embarrassment, Depression

### Functioning

Social interactions, Desire to be with others, Work and enjoyment of life


Range 0 (best) to 100 (worst)



# KSQ-Skin Domain Shows Substantial Improvements in Skin-Related Health Status

KSQ-Skin Domain Mean Change from Baseline to Week 16  
Range: 0 (worst) to 100 (best)

45 mg vs. Placebo:  
 $\Delta 33$ ;  $P=0.0054$




## KSQ assesses impact of CS on health status

- How much skin disease **bothers** the patient
- How much skin disease **concerns** the patient
- How much the patient is **embarrassed** by their skin

# Patient Global Impression of Change (PGI-C) Show Dose-Dependent Improvements

## Patient Global Impression of Change: Improved from Baseline At Week 16



- PGI-C Asks Patients One Question: “Since you started taking study medication, how would you describe the overall change in your sarcoidosis skin symptoms?”
- Patients may check “no change,” one of 3 degrees of improvement (slightly, much, very much), or one of 3 degrees of worsening (slightly, much, very much)
- Of patients who did not report improvement
  - 18% of brepocitinib 15 mg patients reported worsening
  - 43% of placebo patients reported worsening, and 28% reported no change

# Brepocitinib Was Well-Tolerated During Treatment Period, with No SAEs and All AEs Graded Mild or Moderate In Severity

	Brepocitinib 45 mg QD (N=13)	Brepocitinib 15 mg QD (N=11)	Placebo (N=7)
<b>Participants with:</b>			
Adverse Events (AEs)	12 (92%)	6 (55%)	6 (86%)
Death	0	0	0
AEs graded as severe	0	0	0
Serious Adverse Events (SAEs)	0	0	0
AEs leading to treatment discontinuation	1 (8%)	1 (9%)	1 (14%)
AEs leading to study discontinuation	0	0	0
<b>Adverse Events of Special Interest (AESI):</b>			
Creatine Kinase (CK) Increased	1 (8%)	0	0
Anemia	1 (8%)	0	0
Viral reactivation	0	0	0
Malignancy	0	0	0
Major adverse cardiovascular event	0	0	0
Venous thromboembolism	0	0	0
Liver enzyme elevation	0	0	0
Other AESIs	0	0	0

Note: CK elevation was asymptomatic, did not result in study drug discontinuation, and improved with continued treatment. Anemia represented worsening of baseline anemia and improved following study drug discontinuation. Both AESIs were moderate in severity.


Note: Percentages are based on the number of unique participants with an event. Treatment-emergent AEs during treatment period are reported.

For investor audiences only

# Concluding Thoughts

- **Compelling evidence of clinical benefit in a disease with no approved therapies**
  - Brepocitinib demonstrated rapid onset of action and sustained benefit on CSAMI-A at every timepoint measured
  - More than two thirds of brepocitinib 45 mg patients achieved IGA clear/almost clear with two-point improvement, compared to 0 placebo patients
  - Patient reported outcomes support findings from clinician-administered endpoints and highlight evidence of dose-dependent benefit
- **Safety data supports potentially favorable benefit:risk profile, consistent with past brepocitinib studies and safety profile of approved JAK1 and TYK2 targeted agents**
- **Priovant intends to initiate a Phase 3 program by the end of calendar year 2026, following engagement with FDA**
- **Cutaneous sarcoidosis represents third large orphan indication with high patient burden and few/no treatment options in which brepocitinib could potentially be approved within the next few years**

# Brepocitinib Poised to Address >150K Patients With Continuous Catalyst Flow Over the Next 12-24 Months



**Continued Momentum Across Brepocitinib Franchise with Positive Ph2 Data in CS: Ph3 Study Initiation Expected in 2026**

# Additional Program Highlights

**roivant**

A decorative graphic in the bottom right corner consisting of a grid of thin red lines. The grid is formed by a series of vertical lines and a series of horizontal lines that curve upwards from left to right, creating a perspective effect that suggests a curved surface or a dome-like structure.

# IMVT-1402 Highlights

**EXPLORE Phase 3 Study in D2T RA Now Fully Enrolled (N = 170 versus anticipated 120)**



## Potential Best-in-Class Efficacy

IMVT-1402 achieves deep, rapid, dose-dependent IgG reductions; consistent evidence across external and internal clinical trials validates that deeper IgG reductions lead to greater clinical benefit



## Favorable Safety Profile

No significant expected safety issues based on data to-date



## Convenient Administration

Simple subcutaneous autoinjector with 5-10 second self-administration; currently being tested in all IMVT-1402 trials



## Pipeline-in-a-Product Potential


IMVT-1402 is on track to be potential first- and/or best-in-class treatment across 6 indications with potential to address more than 600K patients<sup>1</sup> in the US

# Mosliciguat Highlights

## PHocus Phase 2 Study in PH-ILD Now Fully Enrolled

### PH-ILD

Lung is the primary site of the disease



High dosing burden with multiple daily inhalations



Current therapies are poorly tolerated and can increase cough



Interplay of vascular remodeling and parenchymal scarring



### MOSLICIGUAT

Target delivery to the lungs with deep lung deposition<sup>1</sup>

Convenient once-daily dosing

Well-tolerated, with limited cough and systemic side effects<sup>1</sup>

Promotes vasodilation<sup>1,2</sup> and may exert antifibrotic and anti-inflammatory effects<sup>2</sup>

# Pivotal Period for LNP Litigation



## Moderna Cases



## Pfizer Case



**Revocation of European Patent EP 2279254 is Not Expected to Impact Litigation in Other Jurisdictions**

# Financial Update

**roivant**

A decorative graphic in the bottom right corner consisting of a grid of thin red lines. The grid is composed of vertical and horizontal lines that curve and warp as they move towards the right, creating a sense of depth and movement. The lines are evenly spaced and extend from the bottom left towards the top right of the page.

# Key Financial Items

## Select Income Statement Metrics and Non-GAAP Metrics for the Three Months Ended December 31, 2025

- R&D expense of \$165M; adjusted R&D expense of \$147M (non-GAAP)
- G&A expense of \$175M; adjusted G&A expense of \$71M (non-GAAP)
- Loss from continuing operations, net of tax of \$314M; adjusted loss from continuing operations, net of tax of \$167M (non-GAAP)

## Select Balance Sheet Metrics as of December 31, 2025

- Cash, cash equivalents, restricted cash and marketable securities of \$4.5BN
- No debt on balance sheet
- 715,701,137 common shares issued and outstanding as of February 2, 2026

# Non-GAAP Disclosures

## Reconciliation of GAAP to Non-GAAP Financial Measures (*unaudited, in thousands*)

	Note	Three Months Ended December 31,	
		2025	2024
<b>Loss from continuing operations, net of tax</b>		\$ (313,701)	\$ (208,945)
Adjustments:			
Research and development:			
Share-based compensation	(1)	18,123	9,685
Depreciation and amortization	(2)	548	728
General and administrative:			
Share-based compensation	(1)	86,874	69,386
Depreciation and amortization	(2)	142	1,083
Impairment loss from relocation of Roivant Sciences, Inc.'s headquarters	(3)	17,098	—
Other:			
Change in fair value of investments	(4)	(21,592)	21,314
Change in fair value of liability instruments	(5)	24,416	(2,147)
Estimated income tax impact from adjustments	(6)	21,058	(34,786)
<b>Adjusted loss from continuing operations, net of tax (Non-GAAP)</b>		<b>\$ (167,034)</b>	<b>\$ (143,682)</b>


















### Notes to non-GAAP financial measures:

- (1) Represents non-cash share-based compensation expense.
- (2) Represents non-cash depreciation and amortization expense.
- (3) Represents a loss on impairment of the operating lease right-of-use asset and leasehold improvements for the former U.S. corporate headquarters of Roivant Sciences, Inc., following relocation to a new office space and execution of an agreement to sublease the former office space during the three months ended December 31, 2025.


	Note	Three Months Ended December 31,	
		2025	2024
<b>Research and development expenses</b>		\$ 165,380	\$ 141,595
Adjustments:			
Share-based compensation	(1)	18,123	9,685
Depreciation and amortization	(2)	548	728
<b>Adjusted research and development expenses (Non-GAAP)</b>		<b>\$ 146,709</b>	<b>\$ 131,182</b>
	Note	2025	2024
<b>General and administrative expenses</b>		\$ 175,072	\$ 141,545
Adjustments:			
Share-based compensation	(1)	86,874	69,386
Depreciation and amortization	(2)	142	1,083
Impairment loss from relocation of Roivant Sciences, Inc.'s headquarters	(3)	17,098	—
<b>Adjusted general and administrative expenses (Non-GAAP)</b>		<b>\$ 70,958</b>	<b>\$ 71,076</b>

- (4) Represents the unrealized (gain) loss on equity investments in unconsolidated entities that are accounted for at fair value with changes in value reported in earnings.
- (5) Represents the change in fair value of liability instruments, which is non-cash and primarily includes the loss (gain) relating to the measurement and recognition of fair value on a recurring basis of certain liabilities.
- (6) Represents the estimated tax effect of the adjustments.

# Rich Catalyst Calendar

Program	Vant	Catalyst	Expected Timing
Roivant pipeline growth		New mid/late-stage in-licensing announcements	Ongoing
LNP platform		Summary judgment phase in US Moderna case	Ongoing
LNP platform		Jury trial in US Moderna case	March 2026
Brepocitinib		Expected NDA filing for brepocitinib in dermatomyositis	
Brepocitinib		Topline data from Phase 2 trial in cutaneous sarcoidosis	
Batoclimab		Topline data from both Phase 3 trials in thyroid eye disease	1H 2026
LNP platform		First major hearings in ex-US Moderna cases	1H 2026
Mosliciguat		Topline data from Phase 2 trial in pulmonary hypertension associated with interstitial lung disease	2H 2026
Brepocitinib		Topline data from Phase 3 trials in non-infectious uveitis	2H 2026
IMVT-1402		Topline data from Phase 2 trial in cutaneous lupus erythematosus	2H 2026
IMVT-1402		Topline data from potentially registrational trial in ACPA+ difficult-to-treat rheumatoid arthritis	2H 2026
IMVT-1402		Topline data from potentially registrational trials in Graves' disease	2027
IMVT-1402		Topline data from potentially registrational trial in myasthenia gravis	2027
IMVT-1402		Topline data from potentially registrational trial in Sjögren's disease	2028
IMVT-1402		Topline data from potentially registrational trial in chronic inflammatory demyelinating polyneuropathy	2028

# Over the Next 36 Months (by End of CY 2028), Roivant Will Execute on...



Thank you.

roivant

